EpCAM- AN OLD CANCER ANTIGEN, TURNED ONCOGENIC RECEPTOR AND ITS TARGETING IMMUNOTHERAPY

Abstract

EpCAM is a cell adhesion molecule. Its structure, its expression and the oncogenic potential, and its signaling network and target therapy were in concise reviewed. In recent advances, in addition to PI3K/akt and Raf/MAPK pathway involving in cell survival, anti-apoptosis and proliferation,and malignant initiation and progression, three distinct pathway are illustrated: EpCAM/E-cadherin-catenin-actin cytoskeleton, EpCAM/wint-catenin signaling and its major EpCAM/nuclear signaling presented by Maetzel D in 2009 and Munz M in 2004. Moreover, more accumulated data are needed in detail mechanism. The data may provide its cancer biology and clinical targeting therapy benefits.

Peer Review History:

Received 4 February 2018;   Revised 11 March; Accepted 14 April; Available online 15 May 2018

Received file:        Reviewer's Comments:

Average Peer review marks at initial stage: 4.5/10

Average Peer review marks at publication stage: 7.5/10

Reviewer(s) detail:

Dr. Fatehalrahman F. Magbool, University of Khartoum, Sudan, fmagbool@yahoo.com

Dr. Gülay B Anadolu, Anadolu University, Eskisehir, Turkey, gbuyukko@anadolu.edu.tr